Complete Story
04/04/2022
Priority Health Update
Priority Health Managed Care Committee Member
Flora Varga, Cancer & Hematology Centers of West Michigan
Retacrit supply shortage expected soon
Pfizer informed Priority Health that Retacrit will experience a supply disruption beginning in late May 2022, with a targeted return to supply in early Q4 2022. To see the list of covered alternatives READ MORE
Some Site of Service Restrictions Started April 1st!
Infliximab -The prior authorization requirement for Infliximab products was removed in May 2020 to remove administrative burden. Beginning April 1st, prior authorization is required for the continued administration of infliximab products at a non-preferred site of care. However, if a preferred site of care is utilized, according to the members plan, no authorization will be required.
To review other infusion therapies with site of service restrictions, CLICK HERE
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!